Veloxis Pharmaceuticals announces financial results for the first six months of 2015 and improves the full year outlook

Company Announcement no. 19/2015

To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 26 August, 2015

Veloxis Pharmaceuticals announces financial results for the first six months of 2015 and improves the full year outlook

Highlights:

• On 14 August, 2015 Envarsus® XR was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus.

• On 10 July, 2015 Veloxis has received U.S. Food and Drug Administration (FDA) approval of Envarsus® XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus® XR. Veloxis expects Envarsus® XR to be available to patients in the United States and their physicians by the end of 2015.

• On 12 June, 2015 the U.S. District Court for the District of Columbia ruled in favor of the U.S. Food and Drug Administration (FDA) in the lawsuit filed by Veloxis against FDA.  The Court's ruling left intact FDA's 30 October, 2014 tentative approval of Envarsus® XR (tacrolimus extended-release tablets), which delayed full approval for use in newly transplanted kidney transplant recipients (de novo patients).  Veloxis submitted revised labeling to FDA on 12 June, 2015 with the goal of making Envarsus® XR available for kidney transplant patients who wish to convert from twice-daily tacrolimus products to once-daily Envarsus® XR.

• Top-line results of the ASTCOFF study was announced, A STeady-state Pharmacokinetic COmparison Of all FK-506 Formulations, which demonstrated that once-daily Envarsus® XR (tacrolimus extended-release tablets) exhibits a differentiated pharmacokinetic (PK) profile when compared to twice-daily tacrolimus (Prograf®) or the once-daily tacrolimus product (Astagraf XL®).

• Clinical study data was announced which demonstrated that a lower dose of once-daily Envarsus® XR in African-American kidney transplant patients is sufficient to achieve therapeutic tacrolimus blood concentrations, compared to the daily dose required for twice-daily immediate release tacrolimus, and also results in a lower peak concentration and intra-day fluctuation

• Veloxis reported a net loss of DKK 66.1 million for the first half of 2015 compared to a net loss of DKK 53.1 million for the same period in 2014. The reported net loss is in line with expectations.

• For the first half of 2015, Veloxis’ sales and marketing costs amounted to DKK 19.5 million compared to DKK 13.7 million during the same period in 2014. Research and development costs amounted to DKK 39.1 million compared to DKK 51.0 million during the same period in 2014.

• On 30 June, 2015, Veloxis had cash and cash equivalents of DKK 191.1 million.

• The full year outlook for 2015 is improved. Veloxis now expects an operating loss in the range of DKK 175 - 205 million, and a net loss in the range of DKK 155 - 185 million. Veloxis’ cash position is expected to be in the range of DKK 100 - 130 million at year-end 2015.

Outlook for 2015

The full year outlook for 2015 is improved. Veloxis now expects a net loss in the range of DKK 155 - 185 million. This compares with expectations of DKK 195 - 235 million announced in connection with the annual report for 2014.

The improvement is driven by the granted Orphan Drug status which entitles Veloxis to a waiver of the FDA prescription drug user fees for Envarsus® XR, along with overall cost savings.

Cash and cash equivalents are expected to be in the range of DKK 100 – 130 million at 31 December 2015. This compares with previous expectations of DKK 55 – 95 million.

Conference call

A conference call will be held tomorrow, 27 August, 2015 at 3:00 PM CET (Denmark); 2:00 PM GMT (London), 9:00 AM EST (New York).

To access the live conference call, please dial one of the following numbers:

+45 38 48 75 13 (Denmark)

+44 (0) 20 3427 1909 (UK)

+1 646 254 3360 (USA)

Access code 9488658

Following the conference call, a recording will be available on the company’s website http://www.veloxis.com.

Vedhæftede filer:

260815 Veloxis Result First Six Months 2015.pdf